High incidence of deep venous thrombosis after radical pelvic surgery is well known. Among gynecologic malignancies, ovarian cancer, especially clear cell adenocarcinoma is likely to develop thromboembolism. We report 2 cases of pulmonary thromboembolism and deep vein thrombosis in ovarian clear cell carcinoma with endometriosis and history of IVF-ET during cislatin-irinotecan chemotherapy following the surgery.
Adenocarcinoma ; Adenocarcinoma, Clear Cell ; Endometriosis ; Female ; Incidence ; Ovarian Neoplasms ; Pulmonary Embolism ; Thromboembolism ; Venous Thrombosis

Uterine adenofibroma is an extremely rare benign biphasic neoplasm that is classified into mixed m?llerian tumor. This mass lesion appears to be clinical and histologically benign but it should be differentiated from other malignant neoplasms of uterus. We have experienced a case of uterine adenofibroma in a 53-year-old woman and report this case with a brief review of literature.
Adenofibroma* ; Female ; Humans ; Middle Aged ; Uterus

OBJECTIVE: To evaluate the efficacy of concurrent chemoradiation (CCRT) using 5-flurouracil (5-FU) and cisplatin for locally advanced cervical cancer. METHODS: We reviewed the medical records of 57 patients with locally advanced cervical cancer (stage IIB-IVA and bulky IB2-IIA tumor) who underwent the CCRT at Dong-A University Hospital from January 1997 to June 2007. The CCRT consisted of 5-FU, cisplatin and pelvic radiation. Every three weeks, 75 mg/m(2) cisplatin was administered on the first day of each cycle and 5-FU was infused at the dose of 1,000 mg/m(2)/d from the second day to the fifth day of each cycle. Radiation was administered to the pelvis at a daily dose of 1.8 Gy for five days per week until a medium accumulated dose reached to 50.4 Gy. If necessary, the radiation field was extended to include paraaortic lymph nodes. Consolidation chemotherapy was performed using 5-FU and cisplatin. RESULTS: Fifty-seven patients were enrolled and the median follow-up duration was 53 months (range 7-120 months). The overall response rate was 91.5% (74% complete response and 17.5% partial response). The 5-year overall survival and 3-year progression free survival rates were 69.4% and 74.9%, respectively. During the follow-up period (median 23 months, range 7-60 months), fourteen patients were diagnosed as recurrent disease. CONCLUSION: CCRT with 5-FU and cisplatin which is the primary treatment for patients with locally advanced cervical cancer was effective and well tolerated.
Cisplatin ; Consolidation Chemotherapy ; Disease-Free Survival ; Fluorouracil ; Follow-Up Studies ; Humans ; Lymph Nodes ; Medical Records ; Pelvis ; Uterine Cervical Neoplasms